Antifungal prophylaxis-Where are we today?

Area of Science:

• Neonatal Medicine
• Infectious Diseases
• Pediatric Critical Care

Background:

• Invasive Candida infection (ICI) is a growing concern in premature infants, particularly those of lower gestational ages (GAs).
• Immature immune systems and underdeveloped barriers increase susceptibility to ICI in neonates.
• High mortality and neurodevelopmental impairment (NDI) persist in extremely low birth weight (ELBW) infants with ICI.

Purpose of the Study:

• To review the incidence, risk factors, and prevention strategies for invasive Candida infection (ICI) in premature infants.
• To evaluate the efficacy and safety of fluconazole prophylaxis in high-risk ELBW infants.
• To highlight the need for standardized definitions and reporting of ICI across different gestational ages.

Main Methods:

• Review of existing literature on invasive Candida infection (ICI) in premature infants.
• Analysis of data regarding fluconazole prophylaxis efficacy and safety in extremely low birth weight (ELBW) infants.
• Identification of key risk factors associated with ICI development and outcomes.

Main Results:

• Targeted fluconazole prophylaxis (3 or 6 mg/kg) twice weekly is effective and safe for preventing ICI in high-risk ELBW infants.
• Fluconazole prophylaxis is more effective than nystatin and can be administered intravenously, independent of feeding status.
• Identified risk factors include antibiotic use, parenteral nutrition, central venous catheters, vaginal delivery, specific cephalosporins/carbapenems, and gastrointestinal conditions.

Conclusions:

• Fluconazole prophylaxis is a recommended strategy for preventing ICI in high-risk ELBW infants.
• Standardization of ICI definitions and reporting is crucial for accurate assessment of rates and outcomes.
• Early identification of high-risk infants and timely antifungal prophylaxis can improve outcomes.